Zobrazeno 1 - 10
of 625
pro vyhledávání: '"Winson Y Cheung"'
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 10 (2023)
Aim: The purpose of this retrospective, population-based, observational cohort analysis was to assess whether routine patient-reported outcomes (PRO) monitoring alone has an impact on real-world overall survival (OS) and hospitalizations among indi
Externí odkaz:
https://doaj.org/article/0eb0ab4a266643498f088ade8730d60f
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 13 (2019)
Background: Real-world outcomes for patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) treated with pertuzumab in combination with taxane chemotherapy plus trastuzumab (TaxTP) in the first line setti
Externí odkaz:
https://doaj.org/article/64b0c4fe69da4d6188d8565a815aef99
Autor:
Winson Y. Cheung, Chantelle Carbonell, Vishal Navani, Randeep S. Sangha, Emmanuel M. Ewara, Julia Elia-Pacitti, Sandra Iczkovitz, Tamer N. Jarada, Matthew T. Warkentin
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4382-4396 (2024)
There is limited information on the treatment trajectory and outcomes of patients with advanced cEGFRm NSCLC treated with osimertinib in routine clinical practice in Canada. By using and analyzing population-based administrative data and detailed cha
Externí odkaz:
https://doaj.org/article/968bf2ed25324428abf61531d74ebe18
Autor:
Qi Guan, Suriya J. Aktar, Reka E. Pataky, Mariet Mathew Stephen, Maud Marques, Karen Gambaro, Kahina Rachedi, Katharina Forster, Samara Strub, David Stock, Louis de Léséleuc, Winson Y. Cheung, Stuart Peacock, Christie Farrer, Scott Gavura, Mina Tadrous, Robert C. Grant, Kelvin K. W. Chan
Publikováno v:
Current Oncology, Vol 31, Iss 6, Pp 3591-3602 (2024)
Niraparib was recently funded in Canada for the maintenance treatment of ovarian cancer following platinum-based chemotherapy. However, the drug’s safety profile in the real world remains uncertain. We conducted a cohort study to describe the patie
Externí odkaz:
https://doaj.org/article/7817f7dbf22f4c7abc1ea613261997ef
Autor:
Amanda Jane Williams Gibson, Michelle Liane Dean, Ishjot Litt, Adrian Box, Winson Y. Cheung, Vishal Navani
Publikováno v:
Current Oncology, Vol 31, Iss 5, Pp 2427-2440 (2024)
Introduction: The use of osimertinib in the first-line (1L) setting is an effective treatment option for sensitizing EGFR-mutations (EGFRm+) and has significantly altered the standard of care practice for EGFRm+ disease in Canada. Unfortunately, acqu
Externí odkaz:
https://doaj.org/article/91ab28dc864c46b0b193ce4de85a4dd9
Autor:
Amman Yusuf, Devon J. Boyne, Dylan E. O’Sullivan, Darren R. Brenner, Winson Y. Cheung, Imran Mirza, Tamer N. Jarada
Publikováno v:
BMC Medical Research Methodology, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Laboratory data can provide great value to support research aimed at reducing the incidence, prolonging survival and enhancing outcomes of cancer. Data is characterized by the information it carries and the format it holds. Data c
Externí odkaz:
https://doaj.org/article/77ba153438d140d9b7e9a161a79c415b
Publikováno v:
Cancer Medicine, Vol 13, Iss 13, Pp n/a-n/a (2024)
Abstract Background Lenvatinib (LEN) and atezolizumab + bevacizumab (A + B) have drastically changed the treatment paradigm for advanced hepatocellular carcinoma (HCC). Before these landmark trials, sorafenib (SOR) served as the standard first‐line
Externí odkaz:
https://doaj.org/article/9fffefafa3f9486a9648faba9dbbcc8e
Publikováno v:
Cancer Medicine, Vol 13, Iss 13, Pp n/a-n/a (2024)
Abstract Objectives Randomized controlled trials (RCTs) are the gold standard for evaluating the comparative efficacy and safety of new cancer therapies. However, enrolling patients in control arms of clinical trials can be challenging for rare cance
Externí odkaz:
https://doaj.org/article/919b0151574f4e5088d744bcff3ac847
Autor:
Annalise G. Abbott, Daniel E. Meyers, Golpira Elmi-Assadzadeh, Igor Stukalin, Alessandro Marro, Shannon K. T. Puloski, Don G. Morris, Winson Y. Cheung, Michael J. Monument
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundBone metastases (BoMs) are prevalent in patients with metastatic non-small-cell lung cancer (NSCLC) however, there are limited data detailing how BoMs respond to immune checkpoint inhibitors (ICIs). The purpose of this study was to compare
Externí odkaz:
https://doaj.org/article/8e3e67f0686b45c6b44687246b392205
Autor:
Dylan E. O’Sullivan, Devon J. Boyne, Chelsea Ford-Sahibzada, Jessica A. Inskip, Christopher J. Smith, Kaushik Sripada, Darren R. Brenner, Winson Y. Cheung
Publikováno v:
Current Oncology, Vol 31, Iss 1, Pp 447-461 (2024)
The prognosis of early non-small-cell lung cancer (eNSCLC) remains poor. An understanding of current therapies and outcomes can provide insights into how novel therapies can be integrated into clinics. We conducted a large, retrospective, population-
Externí odkaz:
https://doaj.org/article/f9486525b3da431ea9bbe60f8f56da70